Anika Therapeutics, Inc. (ANIK)
20.81
-0.19
(-0.90%)
USD |
NASDAQ |
Sep 04, 16:00
20.82
+0.02
(+0.07%)
After-Hours: 20:00
Anika Therapeutics Research and Development Expense (Quarterly) : 7.341M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.341M |
| March 31, 2026 | 6.713M |
| December 31, 2025 | 6.452M |
| September 30, 2025 | 6.946M |
| June 30, 2025 | 6.313M |
| March 31, 2025 | 6.059M |
| December 31, 2024 | 6.507M |
| September 30, 2024 | 5.946M |
| June 30, 2024 | 6.682M |
| March 31, 2024 | 6.409M |
| December 31, 2023 | 5.535M |
| September 30, 2023 | 7.791M |
| June 30, 2023 | 8.914M |
| March 31, 2023 | 8.40M |
| December 31, 2022 | 7.749M |
| September 30, 2022 | 7.301M |
| June 30, 2022 | 6.975M |
| March 31, 2022 | 6.157M |
| December 31, 2021 | 6.00M |
| September 30, 2021 | 7.673M |
| June 30, 2021 | 7.293M |
| March 31, 2021 | 6.361M |
| December 31, 2020 | 6.218M |
| September 30, 2020 | 5.217M |
| June 30, 2020 | 4.532M |
| Date | Value |
|---|---|
| March 31, 2020 | 6.05M |
| December 31, 2019 | 4.084M |
| September 30, 2019 | 4.158M |
| June 30, 2019 | 4.165M |
| March 31, 2019 | 4.258M |
| December 31, 2018 | 4.064M |
| September 30, 2018 | 4.232M |
| June 30, 2018 | 4.733M |
| March 31, 2018 | 5.161M |
| December 31, 2017 | 4.266M |
| September 30, 2017 | 5.842M |
| June 30, 2017 | 4.449M |
| March 31, 2017 | 4.23M |
| December 31, 2016 | 2.959M |
| September 30, 2016 | 2.822M |
| June 30, 2016 | 2.792M |
| March 31, 2016 | 2.159M |
| December 31, 2015 | 3.016M |
| September 30, 2015 | 2.062M |
| June 30, 2015 | 1.812M |
| March 31, 2015 | 2.098M |
| December 31, 2014 | 1.983M |
| September 30, 2014 | 2.000M |
| June 30, 2014 | 1.873M |
| March 31, 2014 | 2.288M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | 20.40M |
| MiMedx Group, Inc. | 2.777M |
| ABVC BioPharma, Inc. | 0.0227M |
| Intuitive Surgical, Inc. | 370.40M |
| Enovis Corp. | 31.69M |